South Korean biotechnology company developing antisense oligonucleotide (ASO) therapeutics for CNS, rare and incurable diseases, and specialty indications including cancer, dermatology, and neurodegeneration
South Korean biotechnology company developing antisense oligonucleotide (ASO) therapeutics for CNS, rare and incurable diseases, and specialty indications including cancer, dermatology, and neurodegeneration. It also develops fixed-dose combination medicines for chronic diseases, including hypertension and type 2 diabetes.